Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 19 Issue 3, March 2020

Cancer cell therapies, inspired by the Focus issue.

Cover design: Susanne Harris.


  • Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials.

    • Guangdi Li
    • Erik De Clercq


Top of page ⤴

News & Analysis

  • Bespoke drug development could have regulatory, toxicology and accessibility implications for the entire biopharma sector.

    • Asher Mullard
  • A massive, pioneering trial is underway to assess whether RNA-based modulation of Lp(a) — a form of bad cholesterol that narrows arteries, boosts the risk of blood clots and fans the flames of inflammation — can save lives.

    • Elie Dolgin
  • News in Brief

  • Biobusiness Briefs

  • An Audience With

    • Roche is the world’s top oncology company by sales, earning nearly US$28 billion in 2018 just from its anticancer drugs. And oncologist Sandra Horning has been instrumental in making that possible, shaping the company’s development priorities for the past decade. An oncologist by training, Horning served as Global Head of Clinical Science for Oncology and Hematology at Genentech/Roche from 2009 to 2014, and then as Chief Medical Officer and Head of Global Product Development at the company from 2014 to 2019. In December she retired from this role. She spoke with Asher Mullard about how she has thought about Roche’s cancer pipeline, real-world evidence and more.

      • Asher Mullard
      An Audience With
  • From the Analyst's Couch

Top of page ⤴

Research Highlights

Top of page ⤴


  • γδT cells display potent cytotoxicity towards a large array of haematological and solid tumours while preserving normal tissues. In this Review, Sebestyen et al. analyse the tumour specificity mechanisms of γδT cells and the challenges and opportunities for the use of such cells and their receptors in cancer immunotherapy.

    • Zsolt Sebestyen
    • Immo Prinz
    • Jurgen Kuball
    Review Article
  • The use of allogeneic chimeric antigen receptor T cells from donors has many potential advantages over autologous approaches, such as immediate availability, standardization and the possibility of redosing or combination. This Review analyses the different sources of T cells and technological approaches to produce optimal allogeneic chimeric antigen receptor T cells with limited potential for graft-versus-host disease and increased persistence.

    • S. Depil
    • P. Duchateau
    • L. Poirot
    Review Article
  • Natural killer (NK) cells have a primordial role in tumour immunosurveillance. Given their potent antitumour activity, therapeutic manipulation of NK cells provides an attractive strategy for cancer treatment. This Review discusses new approaches to activate NK cells, increase their proliferation in vivo and increase their capacity to recognize tumour cells.

    • Noriko Shimasaki
    • Amit Jain
    • Dario Campana
    Review Article
Top of page ⤴


Quick links